BofA analyst Jason Gerberry raised the firm’s price target on Vaxcyte to $92 from $80 and keeps a Buy rating on the shares. The firm’s raised target reflects a recent public offering and the firm’s revised nominal peak share partially reflects optionality tied to Phase 2 VAX-31, the analyst tells investors. Though VAX-24 already offers a best-in-category pneumococcal vaccine, BofA believes VAX-31 has “the potential to offer full coverage against all disease causing serotypes and position the company in a dominant position for the foreseeable future,” the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PCVX:
- Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
- Vaxcyte Secures $816.5 Million in Stock and Warrant Sale
- Vaxcyte Announces Pricing of $750 Million Public Offering
- Vaxcyte offering $500M in common stock at $64 per share, Bloomberg says
